Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application
Executive Summary
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
You may also be interested in...
Adolescent Recruitment For COVID-19 Vaccine Trials Is Worry For Operation Warp Speed
However, recruitment for adult trials remains robust, OWS’ Slaoui says.
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
COVID-19 Vaccine EUA Process Compresses Advisory Committee Prep Too
US FDA wants briefing documents when EUA is submitted to accommodate timely advisory committee reviews; unlike traditional assessment process, the agency does not appear interested in engaging in back-and-forth discussions with sponsors about portions of the briefing document that should be made public or redacted.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: